What Happened?
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 13.5% in the afternoon session after the company reported better-than-expected fourth-quarter 2025 revenue and earnings.
For the quarter, Jazz posted revenue of $1.2 billion, representing a 10.1% increase year-over-year and beating analyst estimates. The company's adjusted earnings of $6.64 per share also surpassed expectations. However, this positive performance was contrasted with the company's full-year revenue guidance, which fell short of consensus estimates. Despite the mixed outlook, investors appeared to focus on the strong quarterly results and a significant improvement in profitability. The company's operating margin expanded to 21.2%, up from 17.5% in the same period last year, indicating greater operational efficiency.
Is now the time to buy Jazz Pharmaceuticals? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Jazz Pharmaceuticals’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. But moves this big are rare even for Jazz Pharmaceuticals and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 3 months ago when the stock gained 18.3% on the news that the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its cancer drug, Ziihera. The study tested Ziihera as a first-line treatment for patients with a type of advanced or metastatic gastroesophageal cancer. The trial found that Ziihera, when used with chemotherapy, led to statistically significant and clinically meaningful improvements in progression-free survival compared to the current standard treatment. This means the drug helped patients live longer without their cancer getting worse. Furthermore, when Ziihera was combined with chemotherapy and the checkpoint inhibitor tislelizumab, it also showed a significant improvement in overall survival rates. These strong results suggested that Ziihera-based treatments could become a new standard of care for this form of cancer.
Jazz Pharmaceuticals is up 13.4% since the beginning of the year, and at $196.34 per share, has set a new 52-week high. Investors who bought $1,000 worth of Jazz Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,150.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report, it’s free.